January 6, 2015 Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy
January 5, 2015 Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies
December 30, 2014 Kite Pharma Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 22, 2014 Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, for the Treatment of Refractory Aggressive Non-Hodgkin Lymphoma
December 10, 2014 Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors
December 9, 2014 Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014
December 2, 2014 Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray’s 26th Annual Healthcare Conference
November 18, 2014 Kite Pharma Announces Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
November 18, 2014 Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy
November 17, 2014 Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Investigational Cancer Immunotherapy
November 7, 2014 Capricor Therapeutics to Hold Duchenne Muscular Dystrophy Data Presentation Call on November 18, 2014 at 9:30 a.m. ET
October 31, 2014 Capricor Therapeutics to Hold Third Quarter 2014 Business Update Conference Call on November 12, 2014 at 4:30 p.m. ET
October 29, 2014 Arno Therapeutics’ Executive Selected to Present at 5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference
October 27, 2014 Arno Therapeutics Advances Phase I Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors to Expansion Stage
